http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#Head http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#assertion http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#provenance http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#pubinfo http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#assertion http://purl.obolibrary.org/obo/DOID_0050811 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_0050811 http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00959 http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#association http://www.w3.org/2000/01/rdf-schema#label methylprednisolone tablets are indicated in the following conditions 1 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2 rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis synovitis of osteoarthritis acute nonspecific tenosynovitis post traumatic osteoarthritis psoriatic arthritis epicondylitis acute gouty arthritis 3 collagen diseases during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditis 4 dermatologic diseases bullous dermatitis herpetiformis severe erythema multiforme stevens johnson syndrome severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis 5 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis 6 ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis 7 respiratory diseases symptomatic sarcoidosis berylliosis loeffler s syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis 8 hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemia 9 neoplastic diseases for palliative management of leukemias and lymphomas in adults acute leukemia of childhood 1 edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 11 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis 12 nervous system acute exacerbations of multiple sclerosis 13 miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00959 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#provenance http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#pubinfo http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#sig http://purl.org/nanopub/x/hasSignature Azj7Mq+kvDRCoOgGMHkQ6KpBOH0XR1NIKj5dHtLj7YaaDXiDR3RaAHRBfnhpA1SRf0ekxdGj58AMBzgxJwLj0/DHh4TtVaBTikNyxF1/5AUFKPVSYdZs0ePBCtFwU/wdhk3KGge+FU/zppTt/EbneuRSTO9GOIPetLAJvWwxNC0= http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8 http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8 http://purl.org/dc/terms/created 2021-06-21T10:47:52.493+02:00 http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAoZG0ERKFOMb3FEpOxnEax0NcRn2zbMqOV4Gl_2z5cn8 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs